Will CRISPR/Cas9 technology lead to new development of cell genetic modification? Ubigene

 

Since the world’s first CRISPR/Cas9 clinical trial was carried out in West China Hospital in 2016, gene therapy for cancer has made many gratifying breakthroughs with the help of CRISPR/Cas9, and the breakthrough of CRISPR/Cas9 also attracted everyone's attention. Ubigene has been committed to CRISPR/Cas9 system in cell gene-editing experiments. We are ahead of other companies and promise to guarantee 100% no protein residue in 5000 gene knockout experiments. We also pay attention to the progress of CRISPR/Cas9 system in the field of cancer. Here are a few cases of cancer research using CRISPR/Cas9 system (the following cells are all successful cases of Ubigene)：

Gene editing of Huh-7 cell line——Boost coronavirus, drug metabolism and cancer research

Huh-7 cell line was established in 1982 by Nakabayshi, H. and Sato, J. it is epithelioid and highly heterogeneous. In order to overcome the shortcomings of primary hepatocytes in drug metabolism research, a CRISPR/Cas9 gene modified human hepatocyte line was developed，which studies the effects of gene variation on drug metabolism. Cancer stem cells (CSCs) are closely related to the occurrence and metastasis of cancer. They have the ability of self-renewal and unlimited proliferation, and are the key factors in the development of cancer. Researchers found that the expression of androgen receptor was very high in liver cancer tissues, and was related to Nanog. CRISPR/Cas9 technology was used to knock GFP into Huh-7 cells Nanog, revealing the gender difference in incidence rate of hepatocellular carcinoma, and providing a possible way for the suppression of axons in liver cancer treatment.  click here for the full article

Gene editing CT26.WT cell line——A magic way for colon cancer research and treatment

CT26.WT cell is an invasive mouse colon cancer cell line. By using CRISPR/Cas9 system to edit gene in this cell line, we can generate single or multiple gene knockout, mutation correction or reporter gene insertion transgenic cells. It has a wide range of applications in the study of cancer markers, revealing the mechanism of drug resistance, cancer treatment, cell death and other fields. The researchers used CRISPR/Cas9 system to knock out ATG7 in mouse melanoma cell line B16F10, mouse colon cancer cell line MC38 and mouse colon adenocarcinoma cell line CT26 to study the role of autophagy in the proliferation of mouse cancer cells, and finally revealed the effect of autophagy destruction on immune reactive tumors. click here for the full article

H1299 cells——A tool of studying CRISPR gene therapy for cancer mutation

As an immortalized cell line, H1299 can divide infinitely. The unique feature of this cell line is the lack of P53 protein expression. As a disease model, H1299 cell line plays a very important role in understanding the basic biology of disease, understanding how mutations affect drug response or drug resistance, understanding drug reactivity, target recognition, verifying the mechanism of differences, and even stratification of patients. In one study, researchers used CRISPR/Cas9 technology to construct BCAR1 gene knockout on lung adenocarcinoma cell lines (ncl-h1975 and ncl-h1299), and showing that BCAR1 promoted the proliferation and cell growth of lung adenocarcinoma by up regulating POLR2A. click here for the full article

Ubigene has been working to allow CRISPR/Cas9 technology to be better developed and applied, and our independently developed CRISPR-U™ Technology is 10-20 times more efficient than traditional gene editing, also the breakthrough patented technology for gene modification in vitro and in vivo. Moreover, Ubigene uses CRISPR-U™ to successfully edit genes from more than 100 cell lines. Our leading technology with abundant experience makes our gene editing services more trustworthy!